Company Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases.
The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 1986 |
| IPO Date | Mar 3, 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 536 |
| CEO | Jon P. Stonehouse |
Contact Details
Address: 4505 Emperor Boulevard, Suite 200 Durham, North Carolina 27703 United States | |
| Phone | 919-859-1302 |
| Website | biocryst.com |
Stock Details
| Ticker Symbol | BCRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000882796 |
| CUSIP Number | 09058V103 |
| ISIN Number | US09058V1035 |
| Employer ID | 62-1413174 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jon P. Stonehouse | Chief Executive Officer, President and Executive Director |
| Anthony J. Doyle | Senior Vice President, Chief Financial Officer and Treasurer |
| Alane P. Barnes | Senior Vice President, Chief Legal Officer and Corporate Secretary |
| Dr. William P. Sheridan MBBS | Chief Development Officer |
| Dr. Yarlagadda S. Babu | Chief Discovery Officer |
| Dr. Helen M. Thackray FAAP, M.D. | Chief Research and Development Officer |
| Charles K. Gayer | Senior Vice President and Chief Commercial Officer |
| Michael L. Jones | Executive Director of Finance and Principal Accounting Officer |
| John D. Bluth | Chief Communications Officer |
| Stephanie Angelini | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 27, 2024 | 10-K | Annual Report |
| Feb 26, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 24, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 24, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 18, 2024 | 8-K | Current Report |
| Jan 8, 2024 | 8-K | Current Report |